DXC 008
Alternative Names: DXC-008Latest Information Update: 15 Jun 2024
Price :
$50 *
At a glance
- Originator Hangzhou DAC Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and pharmacokinetics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Jun 2022 Preclinical trials in Solid tumours in China (Parenteral) before June 2022 (Hangzhou DAC Biotech pipeline, June 2022)